Advertisement

Acromegaly: Objectives of Therapy

  • H.-J. Quabbe
Conference paper

Abstract

Untreated acromegaly is associated with increased morbidity and reduced life expectancy [1, 19, 33]. Advances in microsurgical and radiation techniques and the development of new forms of medical treatment have now greatly improved the fate of these patients. On the other hand, refined methods of endocrinological evaluation have shown that complete cure is still not achieved in many patients [22]. New insights into the physiology of GH secretion and its regulation have been gained. More sensitive methods for the radioimmunological determination of GH and the GH-dependent somatomedin-C (Sm-C/IGF I) have made it possible to better define the limits between normal and pathological secretion. This review will therefore attempt to discuss the objectives of treatment especially in terms of GH concentrations and dynamics of secretion following surgical and/or irradiation therapy or during medical treatment.

Keywords

Growth Hormone Pituitary Adenoma Growth Hormone Concentration Growth Hormone Excess High Growth Hormone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R (1980) Epidemiology of Acromegaly in the Newcastle Region. Clin Endocrinol 12: 71–79CrossRefGoogle Scholar
  2. 2.
    Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless J (1982) SMS 201-995: A Very Potent and Selective Octapeptide Analogue of Somatostatin with Prolonged Action. Life Sci 31: 1133–1140Google Scholar
  3. 3.
    Clark RG, Jansson J-O, Isaksson O, Robinson ICAF (1985) Intravenous Growth Hormone: Growth Responses to Patterned Infusions in Hypophysectomized Rats. J Endocrinol 104: 53–61Google Scholar
  4. 4.
    Clemmons DR, Underwood LE, Ridgway EC, Kliman B, Van Wyk JJ (1981) Hyperprolactinemia is Associated with Increased Immunoreactive Somatomedin C in Hypopituitarism. J Clin Endocrinol Metab 52: 731–735CrossRefPubMedGoogle Scholar
  5. 5.
    Daughaday WH, Starkey RH, Saltman S, Gavin JR III, Mills-Dunlap B, Heath-Monnig E (1987) Characterization of Serum Growth Hormone ( GH) and Insulin-Like Growth Factor I in Active Acromegaly with Minimal Elevation of Serum GH. J Clin Endocrinol Metab 65: 617–623Google Scholar
  6. 6.
    Drobny EC, Amburn K, Baumann G (1983) Circadian Variation of Basal Plasma Growth Hormone in Man. J Clin Endocrinol Metab 57: 524–528CrossRefPubMedGoogle Scholar
  7. 7.
    Eastman RC, Gorden P, Roth J (1979) Conventional Supervoltage Irradiation is an Effective Treatment for Acromegaly. J Clin Endocrinol Metab 48: 931–940CrossRefPubMedGoogle Scholar
  8. 8.
    Enberg G, Hall K (1984) Immunoreactive IGF-II in Serum of Healthy Subjects and Patients with Growth Hormone Disturbances and Uremia. Acta Endocrinol (Copenh) 107: 164–170Google Scholar
  9. 9.
    Eversmann T, Lüdeke U, Fahlbusch R, von Werder K (1986) TRH-stimulierte Wachstumshormonsekretion bei Akromegalie. Therapie-Ergebnisse bei 188 Patienten. Dtsch Med Wochenschr 111: 1091–1096CrossRefPubMedGoogle Scholar
  10. 10.
    Feek CM, McLelland J, Seth J, Toft AD, Irvine WJ, Padfield PL, Edwards CRW (1984) How Effective is External Pituitary Irradiation for Growth Hormone-Secreting Pituitary Tumours? Clin Endocrinol 20: 401–408CrossRefGoogle Scholar
  11. 11.
    Goodman HM, Coiro V (1981) Induction of Sensitivity to the Insulin-Like Action of Growth Hormone in Normal Rat Adipose Tissue. Endocrinology 108: 113–119CrossRefPubMedGoogle Scholar
  12. 12.
    Hashida S, Nakagawa K, Ishikawa E, Ohtaki S (1985) Basal Level of Human Growth Hormone (hGH) in Normal Serum. Clin Chim Acta 151: 185–186CrossRefPubMedGoogle Scholar
  13. 13.
    Hendricks CM, Eastman RC, Takeda S, Asakawa K, Gorden P (1985) Plasma Clearance of Intravenously Administered Pituitary Human Growth Hormone: Gel Filtration Studies of Heterogenous Components. J Clin Endocrinol Metab 60: 864–867Google Scholar
  14. 14.
    Herington AC, Cornell HJ, Kuffer AD (1983) Recent Advances in the Biochemistry and Physiology of the Insulin-Like Growth Factor/Somatomedin Family. Int J Biochem 15: 1201–1210CrossRefPubMedGoogle Scholar
  15. 15.
    Isgaard J, Nilsson A, Lindahl A, Jansson JO, Isaksson OGP (1986) Effects of Local Administration of GH and IGF-1 on Longitudinal Bone Growth in Rats. Am J Physiol 250: E367–E372PubMedGoogle Scholar
  16. 16.
    Jaquet P, Guibot M, Jaquet C, Grisoli F, Conte Devolx B, Dumas D, Bert J (1980) Circadian Regulation of Growth Hormone Secretion After Treatment in Acromegaly. J Clin Endocrinol Metab 50: 322–328CrossRefPubMedGoogle Scholar
  17. 17.
    Lamberts SWJ, Uitterlinden P, Verschoor L, van Dongen KJ, Del Pozo E (1985) Long-Term Treatment of Acromegaly with the Somatostatin Analogue SMS 201-995. N Engl J Med 313: 1576–1578CrossRefPubMedGoogle Scholar
  18. 18.
    Liuzzi A, Chiodini PG, Botalla L, Cremascoli G, Silvestrini F (1972) Inhibitory Effect of L-Dopa on GH Release in Acromegalic Patients. J Clin Endocrinol Metab 35: 941–943CrossRefPubMedGoogle Scholar
  19. 19.
    Nabarro JDN (1987) Acromegaly. Clin Endocrinol 26: 481–512CrossRefGoogle Scholar
  20. 20.
    Oppizzi G, Petroncini MM, Dallabonzana D, Cozzi R, Verde G, D, Cozzi R, Verde G, Chiodini PG, Liuzzi A (1986) Relationship Between Somatomedin-C and Growth Hormone Levels in Acromegaly: Basal and Dynamic Evaluation.J Clin Endocrinol Metab 63:13481353CrossRefPubMedGoogle Scholar
  21. 21.
    Quabbe H-J (1978) Endocrinology of Growth Hormone Producing Tumors. In: Fahlbusch R, von Werder K (eds) Treatment of Pituitary Adenomas, First European Workshop on Treatment of Pituitary Adenomas, Rottach-Egern. Thieme, Stuttgart, pp 47–60Google Scholar
  22. 22.
    Quabbe H-J (1982) Treatment of Acromegaly by Transsphenoidal Operation, 90-Yttrium Implantation and Bromocriptine: Results in 230 Patients. Clin Endocrinol 16: 107–119CrossRefGoogle Scholar
  23. 23.
    Quabbe H-J (1983) Acromegaly — An Overview. In: Lamberts SWJ, Tilders FJH (eds) Trends in Diagnosis and Treatment of Pituitary Adenomas, Proceedings of the 3rd European Workshop on Pituitary Adenomas, September, AmsterdamGoogle Scholar
  24. 24.
    Quabbe H-J (1986) Growth Hormone. In: Lightman SL, Everitt BJ (eds) Neuroendocrinology. Blackwell Scientific Publications, Oxford, pp 409–449Google Scholar
  25. 25.
    Quabbe H-J, Schilling E, Helge H (1966) Pattern of Growth Hormone Secretion During a 24-Hour Fast in Normal Adults. J Clin Endocrinol Metab 26: 1173–1177CrossRefPubMedGoogle Scholar
  26. 26.
    Roelfsema F, Frölich M, van Dulken H (1987) Somatomedin-C Levels in Treated and Untreated Patients with Acromegaly. Clin Endocrinol 26: 137–144CrossRefGoogle Scholar
  27. 27.
    Russell SM, Spencer M (1985) Local Injections of Human or Rat Growth Hormone or of Purified Human Somatomedin-C Stimulate Unilateral Tibial Epiphyseal Growth in Hypophysectomized Rats. Endocrinology 116: 2563–2567CrossRefPubMedGoogle Scholar
  28. 28.
    Schaison G, Couzinet B, Moatti N, Pertuiset B (1983) Critical Study of the Growth Hormone Response to Dynamic Tests and the Insulin Growth Factor Assay in Acromegaly After Microsurgery. Clin Endocrinol 18: 541–549CrossRefGoogle Scholar
  29. 29.
    Stolar MW, Baumann G (1986) Secretory Patterns of Growth Hormone During Basal Periods in Man. Metabolism 35: 883–888CrossRefPubMedGoogle Scholar
  30. 30.
    Takahashi Y, Kipnis DM, Daughaday WH (1968) Growth Hormone Secretion During Sleep. J Clin Invest 47: 2079–2090CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Vermeulen A (1987) Nyctohemeral Growth Hormone Profiles in Young and Aged Men: Correlation with Somatomedin-C Levels. J Clin Endocrinol Metab 64: 884–888CrossRefPubMedGoogle Scholar
  32. 32.
    Winkelmann W (1977) Plasma Growth Hormone Response to TRH, LHRH and Bromocryptine in Patients with Acromegaly. Akromegalie-Studiengruppe der DGE. Acta Endocrinol (Copenh) [Suppl 208] 84: 26 (abstract 24)Google Scholar
  33. 33.
    Wright AD, Hill DM, Lowy C, Fraser TR (1970) Mortality in Acromegaly. Q J Med 39:1– 16Google Scholar
  34. 34.
    Yen SSC, Siler TM, DeVane GW (1974) Effect of Somatostatin in Patients with Acromegaly. Suppression of Growth Hormone, Prolactin, Insulin and Glucose Levels. N Engl J Med 290: 935–938CrossRefGoogle Scholar

Copyright information

© Springer-Verlag, Berlin Heidelberg 1988

Authors and Affiliations

  • H.-J. Quabbe
    • 1
  1. 1.Department of Internal Medicine, Section of Endocrinology, Klinikum SteglitzFreie UniversitätGermany

Personalised recommendations